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INTRODUCTION: The prevalence of primary biliary cholangitis (PBC) reported in different countries varies significantly
and seems to have a latitudinal gradient with the highest prevalence reported in higher latitudes, as has
been observed with other autoimmune diseases. This study aimed to determine whether there is a
latitudinal gradient of PBC prevalence in Australia using 2 methods of case ascertainment.
METHODS: We investigated the latitudinal variation of PBC prevalence across the states and territories of Australia
(latitudinal range 18.0°–42.7°S) using pathology-based (private pathology antimitochondrial antibody
results and PBC-specific prescription databases (prescriptions for ursodeoxycholic acid, the only
publicly subsidized treatment for this disease).
RESULTS: PBC prevalence was significantly positively associated with latitude, and the postcodes in the highest
quintile of latitude (encompassing the south coastal areas of the Australian mainland and Tasmania;
latitude range237.75° to242.72°) had a prevalence estimate that was 1.78 times higher using the
pathology-based prevalence estimation than those in the lowest quintile (encompassing tropical and
southern Queensland; latitude range218.02° to227.59°). Comparing prevalence estimates between
states/territories, the result was 2.53 and 2.21 times higher in Tasmania compared with Queensland
when using the pathology-based and prescription-based methods, respectively.
DISCUSSION: Using 2 different case-ascertainment methods, we have demonstrated that prevalence estimates of
PBC vary significantly with latitude in Australia. Further studies are needed to determine whether
factors such as variations in ultraviolet radiation exposure and/or vitaminD levels are responsible for this
observation and to investigate the latitudinal prevalence of PBC in other populations.
SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A610
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INTRODUCTION
Primary biliary cholangitis (PBC) is a chronic cholestatic liver
disease of unknown etiology that causes immune-mediated bile
duct destruction, a process that has the potential to progress to
cirrhosis and liver failure. The disease is characterized by a female
predominance, autoantibodies to mitochondrial antigens (AMA),
and the distinctive histological finding of granulomatous portal
tract inflammation with destruction of small bile ducts.
The etiology of this disease remains largely unknown; at
present, it is believed to be a complex interplay between genetic
susceptibility and environmental factors such as infection (1,2),
xenobiotics (3,4), and tobacco smoking (2,5–7). Previous epide-
miological studies in the north east of England have found clus-
tering of disease, which is highly suggestive of an environmental
factor being linked to disease pathogenesis (8,9). Potential envi-
ronmental factors linked to disease clustering have included toxic
waste sites in New York City (10) and coal mines in Northeast
England (11); however, these associations have not yet been
replicated in other PBC populations.
The reported geographical prevalence of PBC variesmarkedly. A
meta-analysis of 47 population-based studies has identified the
prevalence inNorthAmerica to be 218 permillion and Europe to be
146 per million, both much higher than in the Asia-Pacific region
with a prevalence of 98 permillion (12).We have recently found the
prevalence of PBC to be 81 per million in Victoria, Australia (13).
This contrasts with Newcastle in the north of England where prev-
alence has been reported to be 335 per million (14) and the Calgary
health region of Canada where the prevalence is reported to be 227
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per million (15). This marked variation in disease prevalence is
noteworthy, given the similarity in ethnicity between theAustralian,
UK, and Canadian populations, and raises the possibility that local
environmental factors play a role in PBC pathogenesis. One of the
obvious differences between the Australian, UK, and Canadian
populations is the latitude at which they live and, therefore, levels of
ambient ultraviolet radiation (UVR) exposure. There have been
well-established precedents for increasing disease prevalence at
higher latitudes in other immune mediated diseases, most notably
multiple sclerosis (16,17). Latitudinal gradients of disease prevalence
have also beendescribedwith rheumatoid arthritis and celiac disease
(18–22). A recent retrospective cohort study in theUnitedKingdom
has demonstrated a strong association with PBC and latitude, with
more than double the incidence over a 7° variation of latitude (23).
Epidemiological studies in Australia have the added advantage of
examining a huge variation in latitude, and therefore, it is an ideal
geographic location to evaluate the relationship between latitude and
PBC prevalence.
In this study, we explored whether the prevalence of PBC in
Australia differed by latitude by examining the variation in PBC








million persons IRR (95% CI) aIRR (95% CI)
State
QLD 9 (21.4%) 258 (15.9%) 4,297,330 (22.8%) 60.04 1.00 [reference] 1.00 [reference]
NSW/ACT 10 (23.8%) 474 (29.2%) 7,179,925 (38.0%) 66.02 1.10 (0.95, 1.28) 1.09 (0.94, 1.27)
VIC 10 (23.8%) 583 (35.9%) 5,328,052 (28.2%) 109.42 1.82 (1.57, 2.11) 1.78 (1.54, 2.07)
SA 8 (19.1%) 232 (14.3%) 1,591,722 (8.4%) 145.75 2.43 (2.03, 2.90) 2.39 (1.99, 2.87)
TAS 5 (11.9%) 75 (4.6%) 494,154 (2.6%) 151.77 2.53 (1.96, 3.27) 2.61 (2.01, 3.38)
P, 0.001
Region type
Regional 32 (76.2%) 765 (47.2%) 4,375,269 (23.2%) 174.85 1.00 [reference]
Metro 4 (9.5%) 446 (27.5%) 4,489,204 (23.8%) 99.35 1.30 (1.16, 1.46)
Capital 6 (14.3%) 411 (25.3%) 10,031,219 (53.1%) 40.97 1.23 (1.09, 1.39)
Trend: P, 0.001





218.02,227.59 9 (21.4%) 272 (16.8%) 4,083,429 (21.6%) 66.61 1.00 [reference] 1.00 [reference]
,-27.59, 233.85 8 (19.1%) 272 (16.8%) 3,894,929 (20.6%) 69.83 1.05 (0.89, 1.24) 1.06 (0.90, 1.26)
,-33.85, 235.33 8 (19.1%) 364 (22.4%) 4,162,546 (22.0%) 87.45 1.31 (1.12, 1.54) 1.27 (1.08, 1.49)
,-35.33, 237.75 8 (19.1%) 190 (11.7%) 2,324,882 (12.3%) 81.72 1.23 (1.02, 1.48) 1.27 (1.05, 1.54)
,-37.75, 242.72 9 (21.4%) 524 (32.3%) 4,425,397 (23.4%) 118.41 1.78 (1.54, 2.06) 1.71 (1.47, 1.99)
Trend: P, 0.001 P, 0.001
Sex
Male 179 (11.0%) 9,697,783 (49.4%) 18.46 1.00 [reference] 1.00 [reference]
Female 1,443 (89.0%) 9,947,776 (50.6%) 145.06 7.86 (6.73, 9.18) 7.86 (6.73, 9.18)
P, 0.001 P, 0.001
Age
0–39 79 (4.9%) 10,044,474 (53.2%) 7.87 0.11 (0.09, 0.15) 0.11 (0.09, 0.15)
40–49 186 (11.5%) 2,666,185 (14.1%) 69.76 1.00 [reference] 1.00 [reference]
50–59 378 (23.3%) 2,412,864 (12.8%) 156.66 2.25 (1.88, 2.68) 2.27 (1.90, 2.70)
60–69 434 (26.8%) 1,885,486 (10.0%) 230.18 3.30 (2.78, 3.92) 3.36 (2.83, 3.99)
70–79 335 (20.7%) 1,122,231 (5.9%) 298.51 4.28 (3.58, 5.12) 4.36 (3.64, 5.21)
80–109 210 (13.0%) 758,655 (4.0%) 276.81 3.97 (3.26, 4.83) 3.99 (3.28, 4.87)
Trend: P, 0.001 P, 0.001
Bold indicates statistical significance.
Analyses by Poisson regression, estimating an IRR (95% CI). Adjusted models adjusted for region type.
aTwo-digit postcode regions within each state.





prevalence estimates across the states and territories of Australia
using pathology and PBC-specific prescription databases.
METHODS
Pathology-based PBC prevalence estimation by 2-digit
postcode regions
All positive AMA results (titer . 1:40) and corresponding liver
function tests were provided from the 3 major pathology com-
panies in Australia for the states/territories of Queensland, New
South Wales, the Australian Capital Territory, South Australia,
Victoria, and Tasmania for a 3-year period (2010–2013). Patients
fulfilling the diagnosis of probable PBC (defined as cholestatic
liver function tests [elevation of serum alkaline phosphatase] and
anAMA titer of at least 1:40) were included in this study. Latitude
was geocoded based on patients’ postcode at the time of their
pathology results. Duplicates were excluded based on patient
initials, postcode, and date of birth. Date of birth was used as a
surrogate marker for age at diagnosis because the majority of
AMA testing is performed during the diagnostic workup for PBC.
Services provided through the private sector represent ap-
proximately 60% of all pathology in Australia. Private pathology
services are dominated by 3 large corporate providers (Sonic
Healthcare, Primary Health Care, and Healthscope) which cover
77% of private pathology in Australia (24).The 3major pathology
companies provided a database of all positive AMA results from
January 2010 to January 2013. For each positive AMA result, they
also provided liver function tests for a period of 6months, patient
date of birth, sex, and postcode.
All Australian population data and population proportions
of ancestry were sourced from the 2011 Australian census (25).
Two-digit postcode zones were used to divide Australia into
geographical zones (see Supplemental Figure 1, Supplementary
Digital File, http://links.lww.com/CTG/A610). Self-reported
identification as Australian, English, Scottish, Welsh, and Irish
ancestry was extracted for each 4-digit postcode in the states and
territories in the study, and these then averaged for each of the 2-
digit postcodes. This was performed, so that variation in ancestry
could be evaluated in a multivariate analysis and to see whether
variation in ancestry explained the difference in prevalence at
decreasing latitudes.
PBC prevalence estimation was evaluated by state and also by
quintiles of latitude. Each quintile of latitude represented 20% of
the latitude range for the 2-digit postcode groups.
Ursodeoxycholic acid prescription-based prevalence estimation
by state
The second method of PBC case identification used the urso-
deoxycholic acid (UDCA) prescription data sourced from Medi-
care Australia by state from January 2010 to December 2013 (26).
ThePharmaceutical Benefits Scheme (PBS) ispart of theAustralian
universal health care system that provides subsidized medications
to all Australians. A parallel system exists for Australian veterans:
the Repatriation Pharmaceutical Benefits Scheme. PBC is the only
condition for which UDCA is publicly subsidized in Australia.
Although UDCA can be prescribed for several other rare liver
conditions, government health care-reimbursed prescriptions are
likely to be an accurate marker of PBC prevalence.
Medicare Australia provided the number of PBS and Repa-
triation Pharmaceutical Benefits Scheme prescriptions of UDCA
prescribed in the 3-year period in each state and territory of
Figure 1. Latitudinal variation in PBC pathology-based prevalence by 2-digit postcode regions. Note: an outlier -74 postcode in western Tasmania has been
excluded(seeSupplementaryFigure2,SupplementaryDigitalContent1,http://links.lww.com/CTG/A610).Therewasa linear relationshipbetweenPBCprevalence
and latitude. The circle size in this bubble plot is proportional to the number of PBC cases at each 2-digit postcode region. PBC, primary biliary cholangitis.




Identification of a Latitude Gradient 3
Australia from January 2010 to January 2013 inclusive. Repeat
prescriptions of UDCA are issued every 50 days (based on an
average dose of 500mgbd). Cohort studies have indicated that 90%
of PBC patients are on UDCA (27). Medicare was not able to
provide age and sex of those who had received prescriptions for
UDCA.
To estimate the total number of cases with PBC, the number of
prescriptions dispensed over the 3-year period was divided by
7.31 (calculated by the number of days in the year divided by the
days each individual script lasted, as all repeat prescriptions are
for 50 days [365.25/50]) and then again by 3 (the number of years
of the study period.) This was then divided by population and
then the resultant prevalence multiplied by 0.9, assuming 90% of
PBC cases were taking UDCA (Supplemental Table 4, http://
links.lww.com/CTG/A610). Population denominators for each
state were sourced from the 2011 Australian census, as was the
state-based ancestry data.
The pathology-basedUDCAprevalence estimates and rates of
UDCA prescriptions were evaluated based on ancestry data from
the 2011 census and mutually adjusted with the mean latitude of
each state where the prescriptions were dispensed (Supplemental
Table 5, http://links.lww.com/CTG/A610).
Statistical methods
Predictors of prevalence were evaluated by Poisson regression,
estimating a prevalence ratio (PR). Tests for differences in asso-
ciation by sex and age were assessed bymultiplicative interaction,
the significance of the product term between the primary pre-
dictor and the terms for sex or age denoting the significance of the
difference between groups. All statistical analyses were un-
dertaken in STATA/SE 15.0 (StataCorp, College Park, TX).
This study was approved by the Austin Health Human Re-
search and Ethics Committee.
RESULTS
Pathology-based PBC prevalence estimates by state and latitude
There were 1,622 PBC cases identified using the private pathology
company data, amounting to a prevalence of 85.9 per 1,000,000
(Table 1). In keeping with known disease characteristics, the ma-
jority of cases were female, comprising 88.9% of cases. The post-
codeswith the largest numbersof caseswere the 30and31postcode
zones, encompassing the Melbourne metropolitan area, although
the highest prevalence estimates were in the 74 postcode—
encompassing western Tasmania—and the 55 postcode zone,
which encompasses the north of Adelaide and the Yorke Peninsula
across the St VincentGulf (see SupplementaryTable 1, http://links.
lww.com/CTG/A610). Figure 1 shows the latitudinal variation in
PBC pathology-based prevalence estimates by 2-digit postcode
regions,with an almost linear relationshipbetweenPBCprevalence
and latitude (b5 1.05 [95% CI: 1.03–1.06], P, 0.001).
Evaluating pathology-based PBC prevalence estimates by state/
territory (Table 1), compared with the QLD region (40–49 postcode
zones), the prevalence of PBC was significantly higher in Victoria,
South Australia, and Tasmania. The prevalence of PBC showed a
significant positive latitudinal gradient (ptrend , 0.001), with the
postcodes inTasmaniahavingaprevalence thatwas2.53 timeshigher
than those in Queensland (Figure 2).When the prevalence estimates
were evaluated by quintiles, there was also a positive latitudinal
Figure 2. Pathology-based primary biliary cholangitis prevalence estimates showing a significant difference between VIC, SA, and TAS relative to
Queensland. P values are tests for difference relative to QLD. * denotes significance P, 0.05, and ** denotes significance P, 0.001.





gradient with the postcodes in the highest quintile of latitude
(encompassing the south coastal areas of the Australian mainland
and insular Tasmania; latitude range237.75 to242.72oS) having a
prevalence estimate that was 1.78 times higher than the lowest
quintile of latitude (encompassing tropical and southernQueensland;
latitude range218.02 to227.59oS) (Table 1). When we adjusted for
population aggregation in metropolitan/capital city regions in a
multivariate analysis, these associations persisted (Table 1).
Evaluating associations by sex (Table 2), it was evident that the
regional variation in PBC prevalence was solely present in females,
with males showing no material latitudinal variation. In relation to
age at time of pathology testing (and thus likely age at diagnosis), the
positive latitudinal gradient was present in all age groups from 40
years and above, both by state andby increments of latitude (Table 3).
PBC prevalence varied by ancestry of English, Irish, Scottish,
Welsh, and Australian descent using ancestry data from the 2011
Australian Census (Supplemental table 5, http://links.lww.com/
CTG/A610). However, using either the state/territory-based
proportions of ancestry (Supplemental Table 2, http://links.
lww.com/CTG/A610) or by 2-digit postcode (Supplemental Ta-
ble 3, http://links.lww.com/CTG/A610), the latitudinal associa-
tion was found to be independent of ancestry.
UDCA prescription prevalence estimation by location
and latitude
The pharmaceutical benefit prescription data demonstrated that
there was a statistically significant linear gradient with UDCA
prescriptions, with the prevalence estimation of PBC highest in
Tasmania, followed by Victoria and NSW, and lowest in
Queensland and the Northern Territory (Figure 3; Supplemental
Table 4, http://links.lww.com/CTG/A610) The frequency of
UDCA prescriptions was 2.21 times higher in the state with the
highest median latitude, Tasmania (42.0°S), compared with
Queensland (median latitude 22.5°S) and 4.17 times higher
compared with the Northern Territory (mean latitude 19.5°S).
As with PBC prevalence by pathology, prevalence by UDCA
prescription varied by ancestry of English, Irish, Scottish, Welsh,
and Australian descent. We examined whether ancestry
explained part of the association with latitude. We adjusted for
ancestry and showed that latitude retained its independent as-
sociation with PBC prevalence (Supplemental Table 5, http://
links.lww.com/CTG/A610). The prescription-based prevalence
estimation was not able to be evaluated by sex or age group be-
cause these parameters were not provided byMedicare Australia.
DISCUSSION
This study has demonstrated for the first time that the prevalence
of PBC varies significantly with latitude in Australia. This finding
was demonstrated using 2 separate methods, pathology (AMA-
positive and cholestatic liver function tests) and prescription-
based case identification for the PBC-specific medication UDCA
with both methods demonstrating a strong association with in-
creasing latitude and increasing prevalence of PBC. Postcodes at
higher latitudes had significantly greater prevalence estimations
Table 2. Geographical variation in PBC pathology-based prevalence, by sex
IRR (95% CI)
Test for differenceMales Females
State
QLD 1.00 [reference] 1.00 [reference]
NSW/ACT 0.91 (0.59, 1.42) 1.11 (0.95, 1.31) P 5 0.44
SA 1.26 (0.81, 1.96) 1.87 (1.60, 2.19) P 5 0.16
VIC 1.65 (0.99, 2.76) 1.76 (1.44, 2.15) P 5 0.68
TAS 1.91 (0.84, 4.34) 2.79 (2.12, 3.66) P 5 0.45
Trend: P5 0.010 P , 0.001 P 5 0.82
Region type
Regional 1.00 [reference] 1.00 [reference]
Metro 1.48 (1.03, 2.13) 1.28 (1.13, 1.45) P 5 0.45
Capital 1.48 (1.04, 2.09) 1.01 (0.89, 1.14) P 5 0.043
Trend: P5 0.019 P 5 0.44 P5 0.054
Latitude (continuous) 1.01 (0.98, 1.05) P 5 0.46 1.05 (1.04, 1.06) P , 0.001 P 5 0.13
Latitude (quintiles)
218.02, 227.59 1.00 [reference] 1.00 [reference]
,-27.59, 233.85 0.68 (0.40, 1.14) 1.15 (0.96, 1.37) P5 0.070
,-33.85, 235.33 1.00 (0.64, 1.55) 1.09 (0.92, 1.31) P 5 0.93
,-35.33, 237.75 1.01 (0.57, 1.79) 1.29 (1.06, 1.58) P 5 0.22
,-37.75, 242.72 0.99 (0.63, 1.55) 1.86 (1.58, 2.19) P 5 0.031
Trend: P5 0.64 P , 0.001 P5 0.057
Analyses by Poisson regression, estimating an IRR (95% CI). All models except region type adjusted for region type.
Bold indicates statistical significance.
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of PBC compared with lower latitude postcodes. Using the
pathology-based ascertainment, the prevalence estimates were
2.53 times higher in Tasmania compared with Queensland and
2.21 times higher using the prescription-based case identification.
Our findings are in keeping with a recently published study
identifying a significant association with PBC incidence and
distance from the equator in the United Kingdom (23) with an
odds ratio that increased from 2.16 (95% CI 1.79–2.60) to 4.86
(95% CI 3.93–6.00) over 7° of latitude. There are also recent data
to suggest that there may be an association with latitude and PBC
symptomatology in a study examining the differences between
reported symptoms in British, Italian, Spanish, and Japanese
cohorts of PBC patients adding further weight to the role of lat-
itude in etiopathogenesis (28).
The latitudinal gradient was found for each age group, but
interestingly, it was only present for females and did not seem to
exist for males. It is possible that this is due to the small sample
size with only 179 male cases identified, compared with 1,443
female cases and thus could represent a type II error. We could
not confirm this using the prescription-based case-ascertainment
method because we did not have these data by age or sex.
There is also a well-established association between latitude
and prevalence of multiple other immunologically based diseases
including multiple sclerosis (MS) (17), rheumatoid arthritis, type
I diabetes mellitus, inflammatory bowel disease, myasthenia
gravis, and celiac disease (18–22). In multiple sclerosis, a latitude
gradient has been recognized for more than 40 years. This
gradient was initially believed to be explained by geographically
varying rates of viral infection that then went on to cause disease.
More recently, it has been demonstrated that the gradient in
disease prevalence in MS seems to be explained by differences in
UV exposure, which then potentially leads on to long-term im-
munological effects. There have also been recent studies in-
dicating that latitude may be associated with age of onset in both
multiple sclerosis and rheumatoid arthritis (29–31).
As has been demonstrated with MS, it is possible that the
explanation for the observed latitude gradient of PBC inAustralia
may be due to an effect ofUVRor vitaminD3, produced under the
influence of UVR, exerting a protective effect against the disease
(32,33). The potential protective association of UVR inMS (34) is
believed to be due to an immunomodulatory effect of activated
vitamin D (35). Vitamin D-independent UV modulation of the
immune system has also been reported (36), suggesting theremay
be multiple mechanisms by which ambient UV could impact on
immune function and thus potentially PBC risk. We have also
previously found, in a prevalence study of PBC in Victoria,
Australia, an average annual increase of 7.7 per million per year
from 1991 to 2013 (95%CI: 5.74–8.12). This increased prevalence
may be related to Australians decreasing their sun exposure and
vitamin D levels due to effective SunSmart campaigns (37).
We examined whether differences in ancestry could explain
the association of PBC prevalence with latitude and found that
latitude remained independently associated with prevalence. The
self-reported ancestry, as reported by the 2011 census, has
Table 3. Geographic variation in pathology-based PBC prevalence, by age group
40–49 yo 50–59 yo 60–69 yo 70–79 yo 80–109 yo Test for difference
State
QLD 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
NSW/ACT 1.18 (0.75, 1.86) 1.25 (0.91, 1.72) 0.84 (0.63, 1.11) 1.43 (1.00, 2.04) 0.49 (0.32, 0.76) P 5 0.046
VIC 1.77 (1.13, 2.78) 2.12 (1.55, 2.90) 1.47 (1.12, 1.92) 2.04 (1.42, 2.92) 1.18 (0.80, 1.75) P 5 0.19
SA 2.92 (1.72, 4.95) 1.97 (1.31, 2.96) 1.60 (1.14, 2.26) 2.28 (1.48, 3.53) 1.91 (1.22, 2.99) P 5 0.60
TAS 3.16 (1.48, 6.72) 2.20 (1.26, 3.85) 1.51 (0.89, 2.55) 3.29 (1.90, 5.70) 2.03 (1.06, 3.90) P 5 0.89
Trend: P , 0.001 P , 0.001 P , 0.001 P , 0.001 P , 0.001 P 5 0.84
Region type
Regional 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Metro 1.54 (1.11, 2.15) 1.15 (0.90, 1.48) 1.54 (1.23, 1.93) 1.55 (1.20, 1.99) 1.41 (1.01, 1.97) P 5 0.55
Capital 1.08 (0.74, 1.57) 1.29 (1.01, 1.64) 1.58 (1.26, 1.99) 1.39 (1.06, 1.81) 1.71 (1.25, 2.35) P 5 0.090
Trend: P 5 0.37 P 5 0.040 P , 0.001 P 5 0.004 P 5 0.001 P 5 0.10












218.02,227.59 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
,-27.59, 233.85 1.11 (0.65, 1.90) 1.21 (0.84, 1.75) 1.25 (0.89,1.75) 1.28 (0.85, 1.94) 0.62 (0.36, 1.07) P 5 0.29
,-33.85, 235.33 1.61 (0.98, 2.64) 1.28 (0.88, 1.85) 1.00 (0.70, 1.42) 1.58 (1.05, 2.37) 1.09 (0.67, 1.79) P 5 0.65
,-35.33, 237.75 1.11 (0.60, 2.07) 1.54 (1.03, 2.28) 1.36 (0.93, 2.00) 1.37 (0.86, 2.19) 0.83 (0.45, 1.54) P 5 0.31
,-37.75, 242.72 1.85 (1.15, 2.99) 2.08 (1.48, 2.92) 1.72 (1.26, 2.35) 1.95 (1.33, 2.86) 1.55 (0.98, 2.43) P 5 0.64
Trend: P 5 0.019 P , 0.001 P , 0.001 P 5 0.001 P 5 0.015 P 5 0.90
Analyses by Poisson regression, estimating an IRR (95% CI). All models except region type adjusted for region type.
Bold indicates statistical significance.





considerable variation from state to state, and this could have
been an explanation for the latitude gradient for PBC prevalence,
i.e., populations from 1 particular ethnic group settling in par-
ticular regions of Australia. However, when the multivariate
analysis was adjusted for ancestry, latitude was still associated
with PBC prevalence.
One of the other possible explanations for the latitudinal
gradient could be population aggregation inmetropolitan/capital
city regions; however, when we adjusted for population aggre-
gation in a multivariate analysis, these associations persisted. It is
also important to acknowledge that other environmental factors
besides UVR such as toxic waste exposure, found to be associated
with PBC is anAmerican study (23) or coalmines, associatedwith
clustering of disease in a population study in North East England
(11), could be contributing to the association. These are avenues
to be explored for future research.
A strength of our study is that Australia has a large latitudinal
range while having a uniform health care system. Another
strength is that this study used prevalence estimates from both
positive AMA testing (pathology-based prevalence estimation)
and UDCA prescriptions (prescription-based prevalence esti-
mation). There are however a number of potential flaws in our
data set. AMA-negative PBC (which comprise approximately 5%
of PBC cases) will have not been captured in the pathology-based
estimates. UDCA is also prescribed for a small percentage of
patients who do not have PBC, and thus, these cases may have
been included in the prevalence estimates. Patients who are not
on UDCA would also not have been included in these estimates.
In addition, our prevalence estimates generated from UDCA
dispensing data assume that patients refill their script once the
current amount ofmedication is used. It is likely that some degree
of poor compliance may compromise these estimates. We also
acknowledge that the pathology-based estimates may vary from
state to state as the 3 major private pathology providers did not
necessarily have the same distribution in each state/territory at
the time of this study. These data could not be publicly released.
However, there was a very similar coverage of private health in-
surance across eastern Australia at the time of this study (38), and
thus, there is no reason to believe that the distribution of the
private pathology providers would differ between states. Fur-
thermore, all these potential factors we would expect to affect the
population uniformly, thus although we would expect them to
affect the prevalence estimates, wewould not expect them to affect
the gradient of disease.
The latitude gradient thatwas evident in femaleswith PBCwas
not identified in males. We believe that this at least partly
explained by the small sample size of males in this study. This
requires further evaluation with larger sample sizes, although this
remains difficult in PBCpopulations withmost cases occurring in
females.
Data from the private pathology providers were not released in
Western Australia or the Northern Territory, and thus, pathology-
based prevalence estimation could not be performed for this state
and territory. However UDCA prescription prevalence estimates
were available for the Northern Territory and Western Australia
and the latitudinal gradient was present when data from this ter-
ritory and state were included.WesternAustralia comprises a huge
range in latitude, and a limitation of this studywas thatwewere not
Figure3.Prescription-basedprimary biliary cholangitis prevalence estimates by state showing a significant differencebetweenWA, SA,NSW/ACT, VIC, and
TAS relative to NT. P values are tests for difference relative to NT. * Denotes significance P, 0.05, and ** denotes significance P, 0.001.
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able obtain pathology data for Western Australia, and thus the
numberofPBCcases per 2-digit postcode group,whichwouldhave
enabled further evaluation of the association of latitude and prev-
alence on the west coast of Australia.
In conclusion, we have found for the first time that the prev-
alence estimates of PBC significantly varied with latitude in
Australia using 2 different methods of case ascertainment. The
next direction for future research would be to replicate this
finding in other PBC populations and also to explore whether
there is an association with latitude in other autoimmune liver
diseases. This finding provides novel data to support the possi-
bility that UVR or low vitamin D levels may play a role in disease
etiology. Further case-control or cohort studies are needed to
investigate this hypothesis.
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